All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 26, 2021
Home » Topics » Financings

Financings
%{topic} RSS Feed RSS

Hand holding dollar sign

Wuxi Diagnostics raises $150M in series B financing

Feb. 25, 2021
By David Ho
No Comments
HONG KONG – Wuxi Diagnostic Investment (Cayman) Ltd. has raised $150 million in a series B financing round, while netting a number of new investors along the way. The new investors to come on board include Thermo Fisher Scientific Inc., Shiyu Capital, ABC International Holdings Ltd., Sunland Capital and CCBI Tech Venture.
Read More

Financings for Feb. 25, 2021

Feb. 25, 2021
No Comments
Med-tech firms raising money in public or private financings, including: January AI, Miroculus, Redox, Xtant Medical Holdings.
Read More

Yisheng moves COVID-19 vaccine to clinic after $130M series B

Feb. 25, 2021
By Elise Mak
No Comments
Eight months after Beijing-based Yisheng Biopharma Co. Ltd. unveiled its recombinant protein vaccine candidate for COVID-19, YS-SC2-010, the company raised $130 million in a series B round to pave way for the vaccine to enter clinical trials in the second quarter of this year, the company’s CEO David Shao told BioWorld.
Read More

Xilio advancing immunotherapies to the clinic with $95M series C

Feb. 25, 2021
By Michael Fitzhugh
No Comments
Cancer immunotherapy developer Xilio Therapeutics Inc. has raised $95 million in series C financing to support its efforts to move a duo of tumor-selective candidates into the clinic. IND applications for both its interleukin-2 agonist, XTX-202, and anti-cytotoxic T-lymphocyte-associated protein 4 antibody, XTX-101, are planned for this year.
Read More
DNA illustration
Avexis nexus

Jaguar primed to pounce with portfolio of early stage gene therapies

Feb. 25, 2021
By Michael Fitzhugh
No Comments
Jaguar Gene Therapy LLC, a startup reuniting former Avexis Inc. executives to develop a portfolio of potential treatments for severe genetic diseases, announced its public debut Feb. 25 with more than $40 million in series A financing from co-creator Deerfield Management.
Read More

Financings for Feb. 25, 2021

Feb. 25, 2021
No Comments
Biopharmas raising money in public or private financings, including: 180 Life Sciences, Adamas, Antibe, Aslan, Avita, Cellarity, Cullgen, Halozyme, Inflarx, Predictive Oncology, Vividion.
Read More

Financings for Feb. 24, 2021

Feb. 24, 2021
No Comments
Med-tech firms raising money in public or private financings, including: Davita, Linear Diagnostics, Titan Medical, Truvian Sciences.
Read More

Financings for Feb. 24, 2021

Feb. 24, 2021
No Comments
Biopharmas raising money in public or private financings, including: Aikido, Basilea, Briacell, Celcuity, Cleveland, Halozyme.
Read More

Financings for Feb. 23, 2021

Feb. 23, 2021
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings, including: Molecular Templates, Regor, Sciwind, Takeda, Theravectys.
Read More
Drug vial and syringe

Clover bags $230M in series C, moves COVID-19 vaccine to phase II/III

Feb. 23, 2021
By Elise Mak
No Comments
Chengdu-based Sichuan Clover Biopharmaceuticals Inc., known for its Trimer-Tag technology, raised $230 million in a series C financing round. The proceeds will, most notably, help it advance its COVID-19 vaccine candidate, S-Trimer (SCB-2019), to a global phase II/III trial by June. Following its $43 million series B round in December 2019, Clover said on Tuesday, Feb. 23, that it raised more than $400 million in the last 12 months. The company uses its Trimer-Tag technology platform to produce covalently-trimerized fusion proteins to develop protein-based vaccines and biologic cancer therapies.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 157 158 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing